[go: up one dir, main page]

WO2011021224A3 - Procédé de préparation de (5-méthyl-2-oxo- 1,3-dioxolen-4-yl)méthyl-4-(1-hydroxy- 1 -méthyléthyl)-2-propyl- l-[4-[2-(tétrazol-5-yl)phényl]phényl]méthyl imidazole-5-carboxylate - Google Patents

Procédé de préparation de (5-méthyl-2-oxo- 1,3-dioxolen-4-yl)méthyl-4-(1-hydroxy- 1 -méthyléthyl)-2-propyl- l-[4-[2-(tétrazol-5-yl)phényl]phényl]méthyl imidazole-5-carboxylate Download PDF

Info

Publication number
WO2011021224A3
WO2011021224A3 PCT/IN2010/000546 IN2010000546W WO2011021224A3 WO 2011021224 A3 WO2011021224 A3 WO 2011021224A3 IN 2010000546 W IN2010000546 W IN 2010000546W WO 2011021224 A3 WO2011021224 A3 WO 2011021224A3
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
methyl
dioxolen
methylimidazole
methylethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2010/000546
Other languages
English (en)
Other versions
WO2011021224A2 (fr
Inventor
Manne Satyanarayana Reddy
Chakilam Nagaraju
Srinivasan Thirumalai Rajan
Achampeta Kodanda Ramprasad
Karamala Rama Subba Reddy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MSN Laboratories Pvt Ltd
Original Assignee
MSN Laboratories Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MSN Laboratories Pvt Ltd filed Critical MSN Laboratories Pvt Ltd
Publication of WO2011021224A2 publication Critical patent/WO2011021224A2/fr
Publication of WO2011021224A3 publication Critical patent/WO2011021224A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne un procédé amélioré pour la préparation d'un composé (5-méthyl-2-oxo- 1,3-dioxolen-4-yl)méthyl-4-(1-hydroxy- 1 -méthyléthyl)-2-propyl- l-[4-[2-(tétrazol-5-yl)phényl]phényl]méthyl imidazole-5-carboxylate de formule 1 par l'intermédiaire de (5-méthyl-2-oxo-l,3-dioxolen-4-yl)méthyl 4-(l-hydroxy-1-méthyléthyl)-2-propyl- 1 -[4-[2-(trityltétrazol-5-yl)phényl]phényl] méthylimidazole -5-carboxylate cristallin.
PCT/IN2010/000546 2009-08-19 2010-08-18 Procédé de préparation de (5-méthyl-2-oxo- 1,3-dioxolen-4-yl)méthyl-4-(1-hydroxy- 1 -méthyléthyl)-2-propyl- l-[4-[2-(tétrazol-5-yl)phényl]phényl]méthyl imidazole-5-carboxylate Ceased WO2011021224A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN1975/CHE/2009 2009-08-19
IN1975CH2009 2009-08-19
IN3174CH2009 2009-12-24
IN3174/CHE/2009 2009-12-24

Publications (2)

Publication Number Publication Date
WO2011021224A2 WO2011021224A2 (fr) 2011-02-24
WO2011021224A3 true WO2011021224A3 (fr) 2011-04-28

Family

ID=43607409

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2010/000546 Ceased WO2011021224A2 (fr) 2009-08-19 2010-08-18 Procédé de préparation de (5-méthyl-2-oxo- 1,3-dioxolen-4-yl)méthyl-4-(1-hydroxy- 1 -méthyléthyl)-2-propyl- l-[4-[2-(tétrazol-5-yl)phényl]phényl]méthyl imidazole-5-carboxylate

Country Status (1)

Country Link
WO (1) WO2011021224A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ305129B6 (cs) * 2010-11-24 2015-05-13 Zentiva, K.S. (5-Methyl-2-oxo-1,3-dioxol-4-ylmethyl)-4-(1-hydroxy-1-methyl-propyl)-2-propyl-1-[2´-(1H-tetrazol-5-yl)bifenyl-4-yl-methyl]imidazol-5-karboxylát jako nečistota olmesartan medoxomilu a způsob jeho přípravy
JP6091339B2 (ja) * 2013-05-31 2017-03-08 株式会社トクヤマ オルメサルタンメドキソミルの製造方法
CN106083833B (zh) * 2016-06-30 2020-12-08 浙江华海药业股份有限公司 一种三苯甲基奥美沙坦酯的纯化方法
CN108047208B (zh) * 2018-01-12 2022-03-22 浙江华海药业股份有限公司 一种降低氯沙坦二聚物杂质的方法
CN112778209B (zh) * 2019-11-04 2024-05-14 宜昌东阳光长江药业股份有限公司 一种二酸的制备方法
CN112321575B (zh) * 2020-11-18 2023-07-21 福建天泉药业股份有限公司 一种适合工业化生产的奥美沙坦酯精制方法
CN115583940A (zh) * 2021-07-05 2023-01-10 润都制药(荆门)有限公司 一种制备洛沙坦钾关键中间体的方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1381453A (zh) * 2002-05-17 2002-11-27 浙江省医学科学院 一种新的奥美沙坦的制备方法
WO2006029057A1 (fr) * 2004-09-02 2006-03-16 Teva Pharmaceutical Industries, Ltd. Epuration d'olmesartan medoxomil
US20060149078A1 (en) * 2005-01-03 2006-07-06 Lilach Hedvati Olmesartan medoxomil with reduced levels of impurities
WO2007047838A2 (fr) * 2005-10-20 2007-04-26 Dr. Reddy's Laboratories Ltd. Procede de preparation de l'olmesartan medoxomil
WO2008043996A2 (fr) * 2006-10-09 2008-04-17 Cipla Limited Procédé de préparation d'olmésartan médoxomil tritylé et d'olmésartan médoxomil
WO2009019303A2 (fr) * 2007-08-08 2009-02-12 Lek Pharmaceuticals D.D. Procédé de préparation ou de purification de l'olmésartan médoxomil
WO2010026255A1 (fr) * 2008-09-05 2010-03-11 Krka, Tovarna Zdravil, D.D., Novo Mesto Procédé de préparation d'un intermédiaire d'olmésartan médoxomil
WO2010126014A1 (fr) * 2009-04-28 2010-11-04 第一三共株式会社 Nouveaux cristaux solvates

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1381453A (zh) * 2002-05-17 2002-11-27 浙江省医学科学院 一种新的奥美沙坦的制备方法
WO2006029057A1 (fr) * 2004-09-02 2006-03-16 Teva Pharmaceutical Industries, Ltd. Epuration d'olmesartan medoxomil
US20060149078A1 (en) * 2005-01-03 2006-07-06 Lilach Hedvati Olmesartan medoxomil with reduced levels of impurities
WO2007047838A2 (fr) * 2005-10-20 2007-04-26 Dr. Reddy's Laboratories Ltd. Procede de preparation de l'olmesartan medoxomil
WO2008043996A2 (fr) * 2006-10-09 2008-04-17 Cipla Limited Procédé de préparation d'olmésartan médoxomil tritylé et d'olmésartan médoxomil
WO2009019303A2 (fr) * 2007-08-08 2009-02-12 Lek Pharmaceuticals D.D. Procédé de préparation ou de purification de l'olmésartan médoxomil
WO2010026255A1 (fr) * 2008-09-05 2010-03-11 Krka, Tovarna Zdravil, D.D., Novo Mesto Procédé de préparation d'un intermédiaire d'olmésartan médoxomil
WO2010126014A1 (fr) * 2009-04-28 2010-11-04 第一三共株式会社 Nouveaux cristaux solvates

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YANAGISAVA, H. ET AL.: "Nonpeptide Angiotensin II Receptor Antagonists: Synthesis, Biological Activities, and Structure-Activity Relationships of Imidazole-5-carboaylic Acids Bearing Alkyl, Alkenyl, and Hydroxyalkyl Substituents at the 4-Position and Their Related Compounds", J. MED. CHEM., vol. 39, no. 1, 1996, pages 323 - 338, XP001064743, DOI: doi:10.1021/jm950450f *

Also Published As

Publication number Publication date
WO2011021224A2 (fr) 2011-02-24

Similar Documents

Publication Publication Date Title
WO2007148344A3 (fr) Procédé de préparation d'olmésartan médoxomil
WO2011021224A3 (fr) Procédé de préparation de (5-méthyl-2-oxo- 1,3-dioxolen-4-yl)méthyl-4-(1-hydroxy- 1 -méthyléthyl)-2-propyl- l-[4-[2-(tétrazol-5-yl)phényl]phényl]méthyl imidazole-5-carboxylate
CY2020030I1 (el) Στερεες μορφες 3-(6-(1-(2,2-διφθοροβενζο[d][1,3]διοξολ-5-υλο)-κυκλοπροπανοκαρβοξαμιλο)-3-μεθυλοπυριδιν-3-υλο)-βενζοϊκου οξεος
WO2013042138A3 (fr) Procédé pour la préparation de médicament antifongique triazole, ses intermédiaires et polymorphes de celui-ci
WO2008043996A3 (fr) Procédé de préparation d'olmésartan médoxomil tritylé et d'olmésartan médoxomil
WO2008047082A3 (fr) Dérivé de phtalazinone
BR112013006336A2 (pt) (r)-(e)-2(4-(2-(5-(1-(3,5-dicloro piridin-4-il) etóxi)-1h-indazol-3-il)vinil-1-h-pirazol-1-il) etanol cristalino
WO2015059716A3 (fr) Procédé amélioré pour préparer du ((3s,5r)-5-((1h-1,2,4-triazol-1-yl)méthyl)-5-(2,4-difluorophényl)tétrahydrofuran-3-yl)méthyl-4-méthylbenzènesulfonate
RS52519B (en) SPIROCYCLIC COMPOUNDS WHICH ARE INHIBITORS OF 11-ß HYDROXYL STEROID DEHYDROGENASE TYPE 1
WO2010001021A3 (fr) Procede de realisation d'une couche auto-cicatrisante sur une piece en materiau composite c/c
CL2011002662A1 (es) Preparacion solida que comprende i) acido y ester de 2 - etoxi- 1 - (ciclohexiloxicarboniloxi)etil-2-etoxi-1-[[2-(1h-tetrazol- 5- il) bifenil-4-il]bifenil-4-]metil]bencimidazol-7-carboxilico, acido y 2-etoxi- 1-[[2-(4,5-dihidro-5-oxo-1,2,4-oxadiazol-3-il)bifenil-4-il]metil]-1h-bencimidazol-7- carboxilico, ii) manitol, y iii) amlodipino.
WO2011021804A3 (fr) Capsule en polymère sensible et son procédé de préparation
SI2334668T1 (sl) Postopek priprave intermediata olmesartan medoksomila
MX2009006636A (es) Nuevos intermediarios y procesos utiles en la rpeparacion de {2-[1-(3,5-bis-trifluorometil-bencil)-5-piridin-4-il-1h-[1,2,3]tr iazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona.
ZA201000971B (en) Novel crystalline form of 3-(difluormethyl)-1-methyl-n-(3',4',5'-trifluor[1,1'-biphenyl]-2-yl)-1h-pyrazol-4-carboxamide
WO2009080721A3 (fr) Dérivés de 4-aminopyridine
EP1916246A3 (fr) Procédé amélioré pour la préparation d'olmésartan médoxomil
EP2064202A4 (fr) Nouvelle forme g crystalline de (5s)-5-[4-(5-chloro-pyridin-2-yloxy)-pipéridin-1sulfonylmethyl]-5-methyl-imidazoline-2,4-dione (1) et les intermédiaires
WO2011007368A3 (fr) Procédé amélioré de préparation d'olmésartan
WO2007047838A3 (fr) Procede de preparation de l'olmesartan medoxomil
UY33691A (es) Procedimiento de obtención del olmesartan medoxomilo
MX2012007385A (es) Derivados de aminoalquilpirimidina como anatagonistas del receptor h4 de histamina.
EA201071025A1 (ru) Способ получения [фенилсульфанилфенил]пиперидинов
IL183232A0 (en) PROCESS FOR PREPARING OLMESARTAN MEDOXOMIL AT pH HIGHER THAN 2.5
WO2007013101A8 (fr) Procédé de production de 2-(n-butyl)-3-[[2'-(tétrazol-5-yl)biphényl- 4-yl]méthyl]-l,3-diazaspiro[4.4] non-1-en-4-one

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10809653

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10809653

Country of ref document: EP

Kind code of ref document: A2